Type Segment Analysis: ELISA HEV IgM Tests (Largest Segment) vs Rapid Diagnostics Tests (Fastest-Growing Segment)

In the hepatitis E diagnostic tests market, ELISA HEV IgM tests accounted for the largest share of 52.71% in 2026. Their established position is supported by their ability to detect IgM antibodies associated with recent or acute hepatitis E infection, making them valuable for clinical diagnosis and laboratory-based testing. ELISA-based methods are well suited to structured diagnostic workflows where reliable antibody detection and standardized laboratory procedures are important. Continued awareness of hepatitis E and the need for dependable diagnostic confirmation are supporting sustained use of these tests across healthcare settings.

Rapid diagnostic tests are emerging as the fastest-growing test type as healthcare providers increasingly seek convenient diagnostic approaches that can deliver results with limited laboratory infrastructure. Their simpler workflows and suitability for decentralized testing make them useful in settings where rapid clinical decision-making is important. Greater emphasis on early detection, improved access to infectious disease diagnostics, and the expansion of testing outside conventional laboratory environments are creating favorable conditions for rapid hepatitis E testing. These characteristics are increasing the relevance of rapid diagnostics as healthcare systems pursue more accessible and responsive testing solutions.

End-use Segment Analysis: Hospitals (Largest Segment) vs Diagnostics Laboratories (Fastest-Growing Segment)

Hospitals led the hepatitis E diagnostic tests market, holding a 41.23% share in 2026. Hospitals remain important testing environments because they manage patients presenting with acute symptoms and require diagnostic confirmation to guide appropriate clinical assessment and treatment. Their established laboratory infrastructure and access to specialized healthcare professionals support the integration of hepatitis E testing into broader diagnostic workflows. Increasing attention to infectious disease identification and the need to differentiate hepatitis E from other causes of liver-related symptoms are reinforcing demand within hospital settings.

Diagnostics laboratories are positioned as the fastest-growing end-use segment as healthcare systems increasingly rely on specialized laboratory facilities for efficient and high-quality diagnostic testing. These laboratories can process testing volumes across multiple healthcare providers while offering dedicated expertise and standardized analytical workflows. The growing use of outsourced diagnostics, greater demand for specialized infectious disease testing, and increasing emphasis on timely laboratory confirmation are strengthening their role in hepatitis E diagnosis. Expansion of laboratory-based testing networks is consequently creating additional opportunities for diagnostic test adoption.